115 related articles for article (PubMed ID: 38641307)
1. Doxorubicin-based ENO1 targeted drug delivery strategy enhances therapeutic efficacy against colorectal cancer.
Liu J; Hu X; Yu G; Wang Q; Gu L; Shen J; Zhao Q; Sun H; Wang S; Guo Z; Zhao Y; Ma H
Biochem Pharmacol; 2024 Jun; 224():116220. PubMed ID: 38641307
[TBL] [Abstract][Full Text] [Related]
2. α-enolase promotes tumorigenesis and metastasis via regulating AMPK/mTOR pathway in colorectal cancer.
Zhan P; Zhao S; Yan H; Yin C; Xiao Y; Wang Y; Ni R; Chen W; Wei G; Zhang P
Mol Carcinog; 2017 May; 56(5):1427-1437. PubMed ID: 27996156
[TBL] [Abstract][Full Text] [Related]
3. A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer.
Li Y; Gao Y; Gong C; Wang Z; Xia Q; Gu F; Hu C; Zhang L; Guo H; Gao S
Nanomedicine; 2018 Oct; 14(7):1973-1985. PubMed ID: 29935333
[TBL] [Abstract][Full Text] [Related]
4. Lectin-Mediated pH-Sensitive Doxorubicin Prodrug for Pre-Targeted Chemotherapy of Colorectal Cancer with Enhanced Efficacy and Reduced Side Effects.
Yao M; Ma X; Zhang X; Shi L; Liu T; Liang X; Zhao H; Li X; Li L; Gao H; Jia B; Wang F
Theranostics; 2019; 9(3):747-760. PubMed ID: 30809306
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of an Epidermal Growth Factor Receptor-Targeted Doxorubicin-Peptide Conjugate: Toxicity, Biodistribution, and Efficacy in Mice.
Yang F; Ai W; Jiang F; Liu X; Huang Z; Ai S
J Pharm Sci; 2016 Feb; 105(2):639-649. PubMed ID: 26869425
[TBL] [Abstract][Full Text] [Related]
6. The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo.
Wang C; Wang X; Zhong T; Zhao Y; Zhang WQ; Ren W; Huang D; Zhang S; Guo Y; Yao X; Tang YQ; Zhang X; Zhang Q
Int J Nanomedicine; 2015; 10():2229-48. PubMed ID: 25834435
[TBL] [Abstract][Full Text] [Related]
7. cRGD-decorated biodegradable polytyrosine nanoparticles for robust encapsulation and targeted delivery of doxorubicin to colorectal cancer in vivo.
Gu X; Wei Y; Fan Q; Sun H; Cheng R; Zhong Z; Deng C
J Control Release; 2019 May; 301():110-118. PubMed ID: 30898610
[TBL] [Abstract][Full Text] [Related]
8. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx?
Zou Y; Meng F; Deng C; Zhong Z
J Control Release; 2016 Oct; 239():149-58. PubMed ID: 27569664
[TBL] [Abstract][Full Text] [Related]
9. Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid.
Wang Q; Zhong Y; Liu W; Wang Z; Gu L; Li X; Zheng J; Du H; Zhong Z; Xie F
Drug Deliv; 2019 Dec; 26(1):12-22. PubMed ID: 30691317
[TBL] [Abstract][Full Text] [Related]
10. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
[TBL] [Abstract][Full Text] [Related]
11. Preparation of Liposome Gel by Calcium Cross-Linking Induces the Long-Term Release of DOX to Improve the Antitumor Effect.
Wang L; Wang Y; Ye Z; Yu Y; Wang C; Qiu L; Du X; Zhou S; Wang J; Jiang P
Mol Pharm; 2024 May; 21(5):2394-2405. PubMed ID: 38647653
[TBL] [Abstract][Full Text] [Related]
12. Lipid/Hyaluronic Acid-Coated Doxorubicin-Fe
Liang J; Yang X; Liu D; Cong M; Song Y; Bai S
AAPS PharmSciTech; 2020 Aug; 21(6):235. PubMed ID: 32803528
[TBL] [Abstract][Full Text] [Related]
13. Enhanced anti-tumor efficacy and reduced cardiotoxicity of doxorubicin delivered in a novel plant virus nanoparticle.
Alemzadeh E; Dehshahri A; Dehghanian AR; Afsharifar A; Behjatnia AA; Izadpanah K; Ahmadi F
Colloids Surf B Biointerfaces; 2019 Feb; 174():80-86. PubMed ID: 30445253
[TBL] [Abstract][Full Text] [Related]
14. Tumor-intrinsic CD47 signal regulates glycolysis and promotes colorectal cancer cell growth and metastasis.
Hu T; Liu H; Liang Z; Wang F; Zhou C; Zheng X; Zhang Y; Song Y; Hu J; He X; Xiao J; King RJ; Wu X; Lan P
Theranostics; 2020; 10(9):4056-4072. PubMed ID: 32226539
[No Abstract] [Full Text] [Related]
15. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.
Mamot C; Ritschard R; Wicki A; Küng W; Schuller J; Herrmann R; Rochlitz C
J Drug Target; 2012 Jun; 20(5):422-32. PubMed ID: 22519893
[TBL] [Abstract][Full Text] [Related]
16. Redox-responsive mesoporous selenium delivery of doxorubicin targets MCF-7 cells and synergistically enhances its anti-tumor activity.
Zhao S; Yu Q; Pan J; Zhou Y; Cao C; Ouyang JM; Liu J
Acta Biomater; 2017 May; 54():294-306. PubMed ID: 28267598
[TBL] [Abstract][Full Text] [Related]
17. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.
van Lummel M; van Blitterswijk WJ; Vink SR; Veldman RJ; van der Valk MA; Schipper D; Dicheva BM; Eggermont AM; ten Hagen TL; Verheij M; Koning GA
FASEB J; 2011 Jan; 25(1):280-9. PubMed ID: 20876209
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-Loaded Carbon Dots Lipid-Coated Calcium Phosphate Nanoparticles for Visual Targeted Delivery and Therapy of Tumor.
Zhang J; Zhang H; Jiang J; Cui N; Xue X; Wang T; Wang X; He Y; Wang D
Int J Nanomedicine; 2020; 15():433-444. PubMed ID: 32021189
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of prostate cancer growth using doxorubicin assisted by ultrasound-targeted nanobubble destruction.
Fan X; Wang L; Guo Y; Xiong X; Zhu L; Fang K
Int J Nanomedicine; 2016; 11():3585-96. PubMed ID: 27536100
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor efficacy of doxorubicin-encapsulated halloysite nanotubes.
Li K; Zhang Y; Chen M; Hu Y; Jiang W; Zhou L; Li S; Xu M; Zhao Q; Wan R
Int J Nanomedicine; 2018; 13():19-30. PubMed ID: 29296083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
